- Home
- Companies
- azerbaijan
- disease development
Show results for
Refine by
Industries served
- Medical / Health Care
- Agriculture
- Monitoring and Testing
- Manufacturing, Other
- Chemical & Pharmaceuticals
- Waste and Recycling
- Water and Wastewater
- Health and Safety
- Government
- Food and Beverage
- Energy
- Retail
- Commercial
- Pulp & Paper
- Real Estate
- Maritime/Shipbuild/Water Transport
- Oil, Gas & Refineries
- Environmental
- Soil and Groundwater
- University / Academia / Research
- Construction & Construction Materials
Disease Development Suppliers Serving Azerbaijan
88 companies found
based inWhitestown, INDIANA (USA)
PTS Diagnostics is an innovative point-of-care diagnostics solutions provider that partners with patients and healthcare professionals to provide the right information at the right time to make the right decisions. The company’s name represents the ...
based inRichmond, VIRGINIA (USA)
GLOBAL NUTRITECH is a privately owned company established in 2006 with the vision of using biotechnology research to address problems and inefficiencies in animal production. With offices in both the United States and Turkey, GLOBAL NUTRITECH® ...
based inFoothill Ranch, CALIFORNIA (USA)
At Bal Seal Engineering, we make custom seals, springs, and electrical contacts that improve the performance and reliability of critical equipment used everywhere – from deep sea to deep space. Although they’re often measured in millimeters, our ...
based inWest Lafayette, INDIANA (USA)
Tymora Analytical Operations provides diagnostic development and exosome proteomics contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow ...
based inNewcastle Upon Tyne, UNITED KINGDOM
Newcells offers expert disease modelling services using best in class in vitro platforms and supports drug development by providing robust data for regulatory submissions and the critical decision-making process. Newcells mission is to de-risk the ...
based inSint-Denijs Westrem, BELGIUM
We are a commercial stage medical device company developing the alfapump® platform for the treatment of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump®, is a fully ...
Liver disease, a large and growing market globally. Cirrhosis is late-stage liver disease which occurs when scar tissue (fibrosis) replaces healthy tissue. Alcohol and viral hepatitis B and C are common causes of cirrhosis, although there are many ...
based inBoston, MASSACHUSETTS (USA)
Accelerating Discovery in CNS, Cardiometabolic and Inflammatory Disease. We support our clients to achieve more in their target & biomarker programs. Our expertise, curated & disease enriched clinco-omic cohorts, tools and applications for insight ...
based inIllkirch-Graffenstaden, FRANCE
Emosis develops and provides physicians with first-in-class, on demand, and user-friendly extended in vitro diagnostic products, centered on lab assay kits to be routinely performed on the rapidly growing new generation of flow cytometers, including ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...
based inSeattle, WASHINGTON (USA)
Curi Bio is integrating human iPSC-derived cells, tissue-specific biosystems, and AI-enabled data analytics to accelerate the discovery of new therapeutics. Curi Bio is accelerating the discovery of the next generation of medicines by integrating ...
Curi Bio has a repository of iPSC’s for disease modeling and proprietary technologies for differentiating these cells into myoblasts and cardiomyocytes. Curi has developed in vitro 3D disease ...
based inRouen, FRANCE
Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical ...
Innovation is at the heart of Robocath’s strategy, making R-One™ a unique solution, protected by over 60 international ...
based inSomerville, MASSACHUSETTS (USA)
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted ...
In collaboration with Takeda Pharmaceuticals, we are developing FIN-524 and FIN-525, orally administered, Targeted Consortia product candidates designed for the treatment of ulcerative colitis (UC) and Crohn’s ...
based inMadison, WISCONSIN (USA)
InvivoSciences, Inc. (IVS) is a precision medicine company personalizing the drug development process by introducing patient-derived and gene-edited human samples, including 3D engineered microtissues. Our unique integration of cell & tissue ...
Human engineered tissue (EHT)-based high content analysis can be applied to drug discovery projects at their compound screening and lead optimization stage. Mass-produced human engineered tissues will recapitulate physiological functions of native ...
based inCambridge, UNITED KINGDOM
We’re driven by the shared purpose of breaking new ground in the discovery of new treatments for rare diseases. Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. A broader window of opportunity. Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety ...
based inNangang Distric, TAIWAN
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ...
Studies by X. Yao et al and S. Perinel et al suggest that HCQ can prevent the acidification of intracellular organelles, inhibit lysosomal release of viral genome and interfere with the glycosylation of the angiotensin-converting enzyme-2 (ACE2) ...
based inSchlieren, SWITZERLAND
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our robust and highly physiologically relevant suite of ...
An in vitro PDX model with in vivo-like heterogeneity. 3D InSight™ Tumor Microtissues from Patient-Derived Xenografts (PDX) are custom assay-ready 3D in vitro tumor models engineered to reflect complex tumor biology without the use of ...
based inHopkinton, MASSACHUSETTS (USA)
Psyche Systems is a leading provider of modern laboratory information systems (LIS) designed to support all laboratory test disciplines with high flexibility and configurability. For more than four decades, Psychē Systems has been about continuously ...
No two people’s bodies are exactly the same, so it stands to reason that people will react to medicines and treatments in different ways. While medical treatments can have broad, overall positive results, those results become varied when you ...
based inSan Jose, CALIFORNIA (USA)
LimFlow was founded with the deep belief that more could be done for the millions of patients worldwide suffering from the most severe form of peripheral artery disease — Chronic Limb-Threatening Ischemia (CLTI) — and who are facing the prospect of ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
Sibofimloc is a first-in-class, orally administered small molecule that is specifically designed to reduce the inflammatory cascade underlying Crohn’s disease and remain gut-restricted, to minimize absorption into the bloodstream. ...
